Skip to Main Content

Good morning, everyone, and how are you today? The skies over the Pharmalot campus are decidedly gloomy this morning, but our spirits are sunny, nonetheless. After all, as the Morning Mayor liked to say: Every new day should be unwrapped like a precious gift. So while you tug on the ribbon, we will brew another cup of stimulation — our choice today is maple bourbon — and get busy gathering interesting items for you to peruse. So time to get started. Hope you have a smashing day and, as always, do stay in touch. …

Pfizer is resisting requests for study supplies of its Covid-19 pill, Paxlovid, disappointing researchers who say combining the $22 billion therapy with other drugs might stave off resistance, Bloomberg News reports. The company has not started any combination trials in people, and a review of the database shows no outpatient studies combining Paxlovid, the mainstay U.S. Covid therapy, with other antiviral drugs or antibodies. Some academic researchers and advocacy groups say they are unable to get Paxlovid for human studies that could maintain or improve its effectiveness and expand use.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment